17,637,434 Shares in Haleon PLC Sponsored ADR $HLN Purchased by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD acquired a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 17,637,434 shares of the company’s stock, valued at approximately $158,737,000. Haleon accounts for 3.4% of Mondrian Investment Partners LTD’s portfolio, making the stock its 11th biggest holding. Mondrian Investment Partners LTD owned 0.40% of Haleon as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of HLN. Rahlfs Capital LLC purchased a new stake in shares of Haleon during the third quarter valued at $161,000. Sterling Capital Management LLC grew its holdings in shares of Haleon by 1.9% in the third quarter. Sterling Capital Management LLC now owns 88,039 shares of the company’s stock worth $792,000 after purchasing an additional 1,624 shares during the last quarter. Root Financial Partners LLC bought a new position in shares of Haleon in the third quarter worth about $25,000. Cardinal Capital Management increased its stake in Haleon by 21.9% in the 3rd quarter. Cardinal Capital Management now owns 62,074 shares of the company’s stock worth $559,000 after buying an additional 11,135 shares during the period. Finally, Axxcess Wealth Management LLC increased its stake in Haleon by 2.4% in the 3rd quarter. Axxcess Wealth Management LLC now owns 74,170 shares of the company’s stock worth $668,000 after buying an additional 1,768 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 0.8%

Shares of NYSE HLN opened at $10.29 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The business has a fifty day simple moving average of $9.56 and a two-hundred day simple moving average of $9.51. The firm has a market cap of $45.30 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 2.32 and a beta of 0.14. Haleon PLC Sponsored ADR has a twelve month low of $8.65 and a twelve month high of $11.28.

Haleon Cuts Dividend

The company also recently declared a dividend, which was paid on Thursday, September 17th. Stockholders of record on Friday, August 14th were given a dividend of $0.0642 per share. This represents a dividend yield of 132.0%. The ex-dividend date of this dividend was Friday, August 14th. This is a negative change from Haleon’s previous dividend of $0.1307. Haleon’s dividend payout ratio is currently 30.77%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Berenberg Bank reiterated a “buy” rating on shares of Haleon in a report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Wednesday, September 9th. Zacks Research downgraded shares of Haleon from a “hold” rating to a “strong sell” rating in a research note on Thursday. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Finally, Wall Street Zen lowered shares of Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $4.90.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.